Microbot Medical Inc. announced the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model. As previously announced on December 7, 2023, the study was conducted by three leading interventional radiologists that utilized the LIBERTY Endovascular Robotic Surgical System to perform a total of 96 robotic navigations. Target vessels with surrounding tissue were examined and evaluated microscopically after they were subjected to procedures using a range of commercially available intravascular catheterization devices controlled and manipulated via the LIBERTY Endov vascular Robotic Surgical System.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9201 USD | +0.01% | -6.09% | -43.90% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-43.90% | 13.25M | |
+18.60% | 47.02B | |
+48.77% | 41.86B | |
+0.34% | 41.76B | |
-4.27% | 28.8B | |
+11.83% | 26.05B | |
-22.16% | 19.15B | |
+4.28% | 12.55B | |
+28.53% | 12.34B | |
-3.94% | 11.82B |
- Stock Market
- Equities
- MBOT Stock
- News Microbot Medical Inc.
- Microbot Medical Announces Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Met